MRK
Merck & Co., Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRK
this stock
Merck & Co., Inc.
|
$305.12B | +19.1% | +1.4% | 34.8 | 1.3% |
|
LLY
ELI LILLY & Co
|
$1.12T | +10.8% | +44.7% | 42.2 | 1.0% |
|
JNJ
Johnson & Johnson
|
$618.61B | +24.8% | +6.0% | 29.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$438.31B | +9.4% | +8.6% | 122.2 | 1.2% |
|
NVS
Novartis AG
|
$293.94B | +15.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRK | -4.7% | +4.5% | +13.0% | -3.9% | +19.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -6.0% | +0.4% | +3.9% | -5.0% | +8.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.